hide message

Welcome to the Resource Centre

We make it our mission to work with advocates in civil society, business and government to address inequalities of power, seek remedy for abuse, and ensure protection of people and planet.

Both companies and impacted communities thank us for the resources and support we provide.

This is only possible because of your support. Please make a donation today.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

Interfaith Center on Corporate Responsibility - new report on pharmaceutical firms' responses to AIDS

Get RSS feed of these results

All components of this story

Article
30 November 2006

[PDF] Benchmarking AIDS: 2006 Year End Update

Author: Interfaith Center on Corporate Responsibility [USA]

Pharmaceutical companies continue to fall short on providing access to essential medicines... However, investors found that some companies have taken steps towards improving public health in poor countries and protecting long-term shareholder value... [Includes recent steps by Abbott, Gilead, GlaxoSmithKline, Novartis, and Roche and recommendations for next steps for each of these companies.]

Read the full post here

Article
12 September 2006

Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Author: Compiled by Business & Human Rights Resource Centre

In August 2006, the Interfaith Center on Corporate Responsibility issued a report, "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"...The Business & Human Rights Resource Centre invited the 15 benchmarked companies to respond to the report; the results to date are indicated below.
- Abbott Laboratories statement
- AstraZeneca response
- Boehringer-Ingelheim response
- Bristol-Myers Squibb response
- Eli Lilly - declined to respond
- Gilead Sciences - declined to respond
- GlaxoSmithKline response
- Hoffman-La Roche - declined to respond
- Merck response
- Novartis response
- Pfizer response
- Tibotec (part of Johnson & Johnson) response
- sanofi-aventis: We invited sanofi-aventis to respond; no response has been received.
- Schering-Plough - declined to respond
- Wyeth - press release sent in response to ICCR report

Read the full post here

Article
+ Español - Hide

Author: ComunicaRSE

El Interfaith Center on Corporate Responsibility (ICCR) presentó un informe en el que evalúa a 15 farmacéuticas y concluye que todas están fallando en su aporte a los grandes problemas que enfrentan los países en vías de desarrollo, especialmente en HIV/Sida, malaria y tuberculosis. "Son muertes que podrían evitarse, vidas que podrían alargarse y personas que podrían salvarse, si es que elegimos salvarlas", fue una de las declaraciones más fuertes del reporte...En la categoría "accesibilidad" los autores del reporte sugieren que voluntariamente den la licencia de los genéricos a los productores de países en vías de desarrollo...GlaxoSmithKline...obtuvo los mejores puntajes. Le siguieron...Merck, Bristol-Myers Squibb y Gilead Sciences. Otra empresa que se destacó fue...Sanofi-aventis...Por el contrario, las que obtuvieron peores resultados fueron Abbott...y Boehringer...

🚫Read the full post here

Article
17 August 2006

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

Author: Daniel Rosan, Program Director for Public Health, Interfaith Center on Corporate Responsibility [USA]

[Presentation by Daniel Rosan begins at 54:30; refers to Abbott Laboratories, Bristol-Myers Squibb, Merck, Gilead Sciences, Wyeth]

Read the full post here

Article
17 August 2006

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

Author: Daniel Rosan, Program Director for Public Health, Interfaith Center on Corporate Responsibility [USA]

[identifies pharmaceutical best practice in key areas including research, paediatric needs, drug accessibility, reporting, philanthropy, political engagement; rates 15 top pharmaceutical firms on each practice: Abbott Laboratories, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Eli Lilly, Merck, Novartis, Pfizer, Hoffmann-La Roche (part of Roche), sanofi-aventis, Schering-Plough, Wyeth]

Read the full post here

Article
14 August 2006

New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Author: Interfaith Center on Corporate Responsibility [USA]

The Interfaith Center on Corporate Responsibility released a comprehensive scorecard evaluating the pharmaceutical industry's efforts in the fight against HIV/AIDS...The ICCR report highlights the large disparities between industry best practices in addressing...HIV/AIDS...and the current actions of 15 leading pharmaceutical companies. "We see two major problems - a failure to develop new medicines that address neglected diseases and a lack of access for poor patients to the existing medicines," said Daniel Rosan, ICCR's Program Director for Public Health and author of the report... [companies rated: Abbott Laboratories, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Eli Lilly, Merck, Novartis, Pfizer, Hoffmann-La Roche (part of Roche), sanofi-aventis, Schering-Plough, Wyeth]

Read the full post here